By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen Idec
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display





Company News
Biogen Idec (BIIB) And Gilead Sciences, Inc. (GILD) Join The National Pharmaceutical Council 12/9/2014 9:37:37 AM
Is New Alzheimer’s Drug the Stabilizing Force Biogen Idec (BIIB) Needs? 12/3/2014 2:26:46 PM
Biogen Idec (BIIB) To Present Data From Hematology Programs, Including ELOCTATE™ And ALPROLIX® At American Society of Hematology Annual Meeting 12/3/2014 10:16:19 AM
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/3/2014 6:46:01 AM
FDA Warning: PML Death Associated With Biogen Idec (BIIB)'s Tecfidera 11/26/2014 5:39:58 AM
Biogen Idec (BIIB) To Present At The 2014 Deutsche Bank (DB) BioFEST Conference 11/20/2014 1:49:37 PM
Forward Pharma (FWP) Sues Biogen Idec (BIIB) Over Tecfidera Sales In Germany 11/18/2014 8:01:48 AM
Isis Pharmaceuticals, Inc. (ISIS) Pockets $10 Million Milestone Payment From Biogen Idec (BIIB) 11/6/2014 6:23:17 AM
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce European Medicines Agency Validates ELOCTA&#-0153; (rFVIIIFc) Marketing Authorization Application For Review 11/3/2014 12:23:30 PM
Leading Researchers Join Biogen Idec (BIIB) To Advance Drug Discovery For Neurodegenerative Diseases 10/23/2014 12:20:01 PM
12345678910...
//-->